Scientific excellence and the highest ethical standards

Merck Serono offers a globally integrated research organization with some 1,500 researchers presently working across ten sites all over the world.

We are committed to standing for innovation in human health care based on scientific excellence and the highest ethical standards in order to deliver high-value compounds. Merck Serono’s innovative research will drive the next wave of new and efficacious therapies for patients with significant unmet medical needs.

Merck Serono research brings a balance of small molecules, proteins and monoclonal antibodies into the early clinical development pipeline. A broad base of technological expertise allows us to exploit the full potential of the biological and chemical spheres. The application of new technologies and a broader platform of therapeutic molecules, enhanced by combined experience, is a key factor for innovation.

Our integrated drug discovery process allows a disease-oriented approach, selecting the therapeutic method best suited to treat that disease. Our objective is to bring the best compound to the clinic by a clear Proof-of-Concept strategic approach in order to obtain a confirmed mode of action on patients.

Our research strategy is also supported by strong portfolio and business development from the discovery phase. Our network of alliances with other biotech companies and academic groups fosters a constant flow of innovations into the organization by enriching our disease knowledge and technological capabilities.

Our strong Therapeutic Area-focused drug discovery and development process includes specific disease-related scientific and experimental expertise. A profound understanding of specific disease pathophysiology and related models is essential for successful drug discovery.

In Oncology, our goal is to develop novel therapies that specifically target cancer cells and are more tolerable for patients. Our research is focused on all aspects of disease pharmacology in the Oncology area with the ultimate goal to increase patient survival and improve quality of life.

We focus on all aspects of disease biology and pharmacology research in the Neurodegenerative, Autoimmune and Inflammatory (including dermatological) disease areas with the goal to identify novel therapies that provide symptomatic relief and improve quality of life, slow or stop disease progression.

In Fertility, we are building a portfolio of therapeutic proteins and technologies for improving convenience and success rates for patients undergoing in vitro fertilization.